Krishnaswamy Recognized for Significant Contributions to the
Polymers Industry at ANTEC 2011
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Metabolix
(NASDAQ: MBLX), a bioscience company focused on developing clean,
sustainable solutions for plastics, chemicals and energy, today
announced that Senior Scientist Dr. Rajendra K. Krishnaswamy was honored
by the Society
of Plastics Engineers (SPE) with a lifetime achievement award for
his considerable contributions to the polymers industry. The
Research/Engineering Technology Award for lifetime achievement in
plastics research/engineering was presented to Dr. Krishnaswamy at ANTEC
2011 in Boston, Mass.
"It is a tremendous honor to receive one of SPE's lifetime achievement
awards, which would not be possible without the support of,
encouragement from and collaboration with the Metabolix team," said Dr.
Krishnaswamy. "I am looking forward to continuing my association with
the Metabolix team, creating new, innovative advances that will benefit
the entire plastics industry."
Dr. Krishnaswamy leads the development of a family of biobased and
biodegradable polymers for film and blow-molding applications at
Metabolix. His approach to product development combines a theoretical
understanding of polymer rheology with traditional scientific methods —
from design-of-experiments (DOE) approaches to new product development.
A number of Dr. Krishnaswamy's innovations have led to advancements in
Mirel™, a commercialized bioplastics offering from Telles, a joint
venture between Metabolix and Archer Daniels Midland Company.
"We've always been incredibly proud of Dr. Krishnaswamy's achievements
in the polymer space and are very fortunate to have him on our team,"
said Rick Eno, CEO of Metabolix. "Under Dr. Krishnaswamy's guidance, his
team developed a unique patented formulation of new PHA biopolymers,
thus playing an integral role in Metabolix's ability to provide the
market with more sustainable bioplastic materials. SPE's lifetime
achievement award reflects Dr. Krishnaswamy's many contributions to the
research and development of biobased and biodegradable plastics."
Prior to joining the company in 2006, Dr. Krishnaswamy spent nine years
in the polymer science group at Chevron Phillips Chemical Company. He
currently serves on the editorial boards of the Journal of Plastic
Film and Sheeting and the Encyclopedia of Polymer Science and
Technology. Additionally, he serves on the Engineering Properties
and Structure Division (EPSDIV) and bioplastics boards of SPE, as well
as the materials science board of the American Institute of Chemical
Engineers (AIChE). To date, Dr. Krishnaswamy has co-authored more than
40 peer-reviewed papers and over 25 patents and patent applications, and
has been an invited speaker at many conferences and universities
worldwide.
About Metabolix
Founded in 1992, Metabolix, Inc. is an innovation-driven bioscience
company focused on providing sustainable solutions for the world's needs
for plastics, chemicals and energy. The Company is taking a systems
approach, from gene to end product, integrating sophisticated
biotechnology with advanced industrial practice. Metabolix is now
developing and commercializing Mirel™, a family of high-performance
bioplastics which are biobased and biodegradable alternatives to many
petroleum-based plastics, through Telles, a joint venture between
Metabolix and Archer Daniels Midland Company. Metabolix is also
developing biosourced industrial chemicals and a proprietary platform
technology for co-producing plastics, chemicals and energy, from crops
such as switchgrass, oilseeds and sugarcane.
For more information, please visit www.metabolix.com.
(MBLX-G)
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements which are made
pursuant to the safe harbor provisions of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. The forward-looking statements in this release do
not constitute guarantees of future performance. Investors are cautioned
that statements in this press release which are not strictly historical
statements, including, without limitation, statements regarding
expectations for advances in Metabolix technology, constitute
forward-looking statements. Such forward-looking statements are subject
to a number of risks and uncertainties that could cause actual results
to differ materially from those anticipated and are detailed in
Metabolix's filings with the Securities and Exchange Commission.
Metabolix assumes no obligation to update any forward-looking
information contained in this press release or with respect to the
announcements described herein.
Media:
Schwartz Communications
Keith Giannini or Jen Barlow,
781-684-0770
metabolix@schwartzcomm.com
or
Investors:
ICR
James
Palczynski, 203-682-8229
james.palczynski@icrinc.com
Source: Metabolix
News Provided by Acquire Media
